HomeCompareAFMD vs PLD

AFMD vs PLD: Dividend Comparison 2026

AFMD yields 1101.93% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AFMD wins by $44144476.10M in total portfolio value
10 years
AFMD
AFMD
● Live price
1101.93%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44144482.00M
Annual income
$37,457,590,875,373.99
Full AFMD calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — AFMD vs PLD

📍 AFMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAFMDPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AFMD + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AFMD pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AFMD
Annual income on $10K today (after 15% tax)
$93,663.91/yr
After 10yr DRIP, annual income (after tax)
$31,838,952,244,067.89/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, AFMD beats the other by $31,838,948,205,951.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AFMD + PLD for your $10,000?

AFMD: 50%PLD: 50%
100% PLD50/50100% AFMD
Portfolio after 10yr
$22072243.96M
Annual income
$18,728,797,813,049.59/yr
Blended yield
84.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

AFMD
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$7.50
+4032.2% upside vs current
Range: $5.00 — $10.00
Altman Z
-25.6
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AFMD buys
0
PLD buys
0
No recent congressional trades found for AFMD or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAFMDPLD
Forward yield1101.93%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$44144482.00M$5.91M
Annual income after 10y$37,457,590,875,373.99$4,750,725.19
Total dividends collected$43640208.51M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$7.50$136.00

Year-by-year: AFMD vs PLD ($10,000, DRIP)

YearAFMD PortfolioAFMD Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$120,893$110,192.84$11,241$540.96+$109.7KAFMD
2$1,374,358$1,245,002.32$13,019$991.13+$1.36MAFMD
3$14,698,300$13,227,737.75$15,801$1,870.97+$14.68MAFMD
4$147,938,657$132,211,475.91$20,609$3,701.21+$147.92MAFMD
5$1,401,949,387$1,243,655,023.61$29,919$7,867.97+$1401.92MAFMD
6$12,514,637,219$11,014,551,374.87$50,631$18,617.74+$12514.59MAFMD
7$105,280,812,731$91,890,150,906.24$105,528$51,352.20+$105280.71MAFMD
8$835,114,369,934$722,463,900,312.29$287,364$174,449.42+$835114.08MAFMD
9$6,249,430,961,556$5,355,858,585,726.27$1,081,760$774,280.77+$6249429.88MAFMD
10$44,144,482,004,238$37,457,590,875,373.99$5,908,209$4,750,725.19+$44144476.10MAFMD

AFMD vs PLD: Complete Analysis 2026

AFMDStock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Full AFMD Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this AFMD vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AFMD vs SCHDAFMD vs JEPIAFMD vs OAFMD vs KOAFMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.